PPAP-HCl

PPAP-HCl, the hydrochloride salt of (-)-(R)-1-phenyl-2-propylaminopentane, is an experimental catecholaminergic activity enhancer (CAE) compound originally synthesized by Jozsef Knoll and colleagues at Semmelweis University in Budapest in the late 1980s as a structural derivative of selegiline (L-deprenyl) designed to retain the catecholaminergic enhancer activity of the parent compound while eliminating its monoamine oxidase (MAO) inhibitory property. The compound occupies a mechanistically distinct position in the catecholaminergic pharmacology space: at low-to-moderate concentrations, PPAP potentiates the impulse-propagation-mediated (action-potential-dependent) release of dopamine and norepinephrine from catecholaminergic nerve terminals without producing the uncontrolled, impulse-independent monoamine efflux characteristic of amphetamine and methamphetamine. This "enhancer" mechanism, first formally described by Knoll in 1992 and subsequently elaborated in a series of publications through 2005, operates independently of MAO inhibition, presynaptic autoreceptor blockade, and classical reuptake inhibition, and instead potentiates the vesicular exocytotic release event coupled to the arriving action potential. Recent pharmacological characterization reported in 2025 has expanded the mechanistic profile by demonstrating that PPAP also acts as a potent dopamine transporter (DAT) reuptake inhibitor with an IC50 of 57.5 nM, a norepinephrine transporter (NET) inhibitor at 571 nM, and a weak serotonin transporter (SERT) inhibitor at 19,000 nM, placing it in a dual-mechanism category that combines enhancer activity with catecholamine reuptake inhibition. Additional evidence suggests that PPAP and related synthetic enhancer compounds may exert their catecholaminergic effects through agonism at trace amine-associated receptor 1 (TAAR1), an intracellular G-protein-coupled receptor that modulates vesicular dopamine release through protein kinase C (PKC)-mediated phosphorylation of exocytotic machinery.

In preclinical behavioral pharmacology, PPAP facilitates learning and retention in shuttle-box avoidance paradigms, potently antagonizes tetrabenazine-induced behavioral depression, reduces immobility in the forced swimming test, and increases locomotor activity across a broad dose range (2 to 50 mg/kg in rodents) without the narrow therapeutic window and stereotypy induction that characterize amphetamine-class stimulants. The therapeutic index in animal models exceeds that of amphetamine. Structure-activity relationship studies identified the (R)-enantiomer as the pharmacologically active form, while the racemic mixture (designated MK-306) retains partial activity. PPAP served as the reference catecholaminergic activity enhancer compound in the Knoll laboratory and led directly to the development of the more potent and serotonergically active successor compound BPAP [(-)1-(benzofuran-2-yl)-2-propylaminopentane] in 1999. PPAP has been proposed as a candidate for clinical development in depression, attention deficit hyperactivity disorder (ADHD), and Alzheimer's disease, though no human clinical trials have been completed or published. The compound is not approved by any regulatory authority for therapeutic use and is available exclusively as a research-grade preparation. This monograph reviews the chemistry, synthesis, and stereochemistry of PPAP-HCl; the dual enhancer and reuptake-inhibitor pharmacology; the preclinical behavioral and neurochemical evidence base; the comparative assessment of five catecholaminergic and monoaminergic enhancer or stimulant candidates against PPAP on five competency standards; and the sourcing, reconstitution, and handling considerations for laboratory work.